Videos
Clinical Conversations by Experts
View all
Clinical Case-Based Learning: Virtual Tumor Board in Advanced Prostate Cancer
- Tumor Board Reviewing the Use of PSMA PET in the Care of Patient Who Underwent Fluciclovine for Prostate Cancer - Session 1 Case 6
- Tumor Board Reviewing PSMA PET in the Care of Patient with Gleason 4+4=8 GG 4, 6 Cores on Left, Gleason 4+3=7 GG, 6 Cores on Right Prostate Adenocarcinoma, Session 1 Case 4 - H Jacene, A Kibel, P Nguyen & A Morgans View all Clinical Case-Based Learning: Virtual Tumor Board in Advanced Prostate Cancer videos
Treatment Considerations in First Line Setting of Metastatic Castration-Resistant Prostate Cancer
- Safety and Disease Related Outcomes of mCRPC Patients Who Were Treated with Radium-223 Then 177Lu-PSMA (RALU) - Neal Shore
- The Association Between the Time Interval Between Sequential Treatment With Radium-223 Therapy and 177Lu-PSMA in the RALU Study - Kambiz Rahbar
- Sequencing Radiopharmaceuticals: Efficacy and Safety Data of Radium-223 Followed by Lutetium-177-PSMA in the RALU Study - Oliver Sartor
- Radiopharmaceuticals in the Treatment Landscape of Metastatic Castration-Resistant Prostate Cancer – A Cased Based Review - Phillip Koo, Neal Shore, & Alicia Morgans View all Treatment Considerations in First Line Setting of Metastatic Castration-Resistant Prostate Cancer videos
ASCO 2023
- The Relationship Between a Priori Defined Prognostic Risk Groups and Overall Survival in Men with mCRPC - Susan Halabi
- Prostate Cancer and Veterans Health: A Spotlight on the Groundbreaking Initiatives at the VA System - Hiten Patel
- Tumour Factors and the Variation in Non-Muscle Invasive Bladder Cancer Recurrence After Transurethral Resection Surgery Between Sites: Results from the RESECT Study - Kevin Gallagher View all ASCO 2023 videos
Artificial Intelligence in Prostate Cancer 2022
- Personalizing Prostate Cancer Therapy Using AI-based Predictive Biomarkers - Paul Nguyen
- Beyond Genomics: AI Informing Decision Making in Prostate Cancer – Ashley Ross
- The Artera AI Model: Advancing Personalized Medicine in Prostate Cancer Treatment | Dan Spratt & Alicia Morgans Discuss NEJM Evidence Manuscript View all Artificial Intelligence in Prostate Cancer 2022 videos
Featured Videos
Probing the Promising Future of Anti-HER2 Therapies for Micropapillary Bladder Cancer - Jeffrey Ross
Quality of Life and Patient-relevant Endpoints With Darolutamide in the ARASENS Trial - Karim Fizazi
Association of Inherited Mutations in DNA Repair Genes with Localized Prostate Cancer – Kara Maxwell
The Stakeholders in Operationalizing an Integrated PSMA Imaging and Therapies Clinic - Kendra Harris
Patient Selection for ADT Treatment with the Oral GnRH Antagonist in Clinical Practice - Ashley Ross
Prostate cancer genomic classifier Videos
Latest Videos
Bladder Cancer Videos
Probing the Promising Future of Anti-HER2 Therapies for Micropapillary Bladder Cancer - Jeffrey Ross
DNA Based Markers in High-risk Non-Muscle Invasive BCG Unresponsive Bladder Cancer - Alexander Wyatt
A Patient Perspective on High-Risk Non-Muscle Invasive BCG Unresponsive Bladder Cancer- Karen Sachse
Recent Conference Coverage
Conference Highlights Written by Physician-Scientist
ASCO 2023 Conference Highlights
- ASCO 2023: Digital Histopathology-Based Multimodal Artificial Intelligence Scores Predict Risk of Progression in a Randomized Phase III Trial in Patients with Nonmetastatic Castration-Resistant Prostate Cancer
- ASCO 2023: When to Play the Systemic Therapy Card
- ASCO 2023: When Is Stereotactic Ablative Body Radiotherapy an Option?
AUA 2023 Conference Highlights
- AUA 2023: Optimal Management of cN+ Muscle Invasive Bladder Cancer
- AUA 2023: Intermediate Risk NMIBC: Surveillance and Treatment Challenges
- AUA 2023: Perioperative Outcomes of Radical Cystectomy Following Neoadjuvant Gemcitabine, Cisplatin and Atezolizumab
Recent Physician-Scientist Review Articles
State of the Evidence Review Articles
Advanced Prostate Cancer
- PARP Inhibitor Plus Androgen Receptor Signaling Inhibitor Combinations: Will This Be The Future of mCRPC First-Line Therapy?
Written by Rashid K. Sayyid, MD MSc & Zachary Klaassen, MD MSc
- Artificial Intelligence and Prostate Cancer: Risk Stratification After Primary Therapy, ADT Treatment Intensification, and Evaluation of Metastatic Disease
Written by Zachary Klaassen, MD, MSc and Rashid K. Sayyid, MD, MSc
mHSPC
- Prostate Radiotherapy for De Novo, Low Volume Metastatic Hormone Sensitive Prostate Cancer: Is There Benefit?
Written by Rashid Sayyid, MD, MSc and Zachary Klaassen, MD, MSc
- Treatment Intensification in Metastatic Hormone Sensitive Prostate Cancer (mHSPC): Metachronous Low Volume mHSPC
Written by Rashid K. Sayyid, MD MSc and Zachary Klaassen, MD MSc
Transformative Evidence
Curated by Clinicians: Educational Forum with Videos, Abstracts and Conference Information
ARASENS Trial
Darolutamide: A Review in Metastatic Hormone-Sensitive Prostate Cancer.Darolutamide (NUBEQA®) is an oral androgen receptor inhibitor (ARi) that is approved for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT) and docetaxel.
Read MoreBladder Cancer Detection
Photocure Partner Asieris announces completion of enrollment for Hexvix Phase III clinical trial in China
Reno, Nevada (UroToday.com) -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) has communicated today that it has completed patient enrollment for the Hexvix® Phase III bridging trial. Read More
Clinical Application And Utility Of PYLARIFY
Lantheus Presentations at the European Association of Nuclear Medicine Annual Meeting Showcased Artificial Intelligence Data
Reno, Nevada (UroToday.com) -- Lantheus Holdings, Inc., a company committed to improving patient outcomes through diagnostics, radiotherapeutics, and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease, showcased artificial intelligence (AI) data at the 2022 European Association of Nuclear Medicine (EANM) Annual Meeting in Barcelona, Spain. Read More
ARAMIS Trial
Addition of Docetaxel to Androgen Receptor Axis–targeted Therapy and Androgen Deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis
Context: Randomized controlled trials (RCTs) have shown that addition of docetaxel or androgen receptor axis–targeted therapy (ARAT) to androgen deprivation therapy (ADT) or addition of ARAT to ADT and docetaxel improves overall survival (OS) in metastatic hormone-sensitive prostate cancer (mHSPC). However, it is unknown whether docetaxel, when given as part of triplet therapy, has an independent OS benefit. Read More
VISION Trial
FDA Grants Priority Review for Investigational Targeted Radioligand Therapy 177Lu-PSMA-617 for Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Novartis announced that the US Food and Drug Administration (FDA) has accepted and granted Priority Review to the company’s New Drug Application (NDA) for 177Lu-PSMA-617, an investigational targeted radioligand therapy for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in the post androgen receptor pathway inhibition, post-taxane-based chemotherapy setting. Read More